Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6446674 | 0.92 | CYP1A2 (0.52) | CYP1A2CYP3A4RAB9AHSD17B10KDM4E | |
| SCHEMBL6444202 | 0.86 | CYP1A2 (0.38) | CYP1A2CYP3A4RAB9AKMT2AMAPK1 | |
| SCHEMBL6446627 | 0.84 | CYP1A2 (0.50) | CYP1A2CYP3A4RAB9AHSD17B10KDM4E | |
| SCHEMBL6446282 | 0.82 | RAB9A (0.53) | RAB9AHSD17B10KDM4EMAPK10KMT2A | |
| SCHEMBL6447518 | 0.76 | RAB9A (0.51) | RAB9AHSD17B10KDM4EMAPK10KMT2A | |
| SCHEMBL7426695 | 0.73 | HPGD (0.46) | RAB9AKDM4EKMT2AALDH1A1MAPK1 | |
| SCHEMBL11627166 | 0.70 | CYP1A2 (0.75) | CYP1A2CYP3A4RAB9AHSD17B10KDM4E | |
| SCHEMBL27660006 | 0.70 | HPGD (0.63) | CYP1A2CYP3A4HSD17B10KMT2AALDH1A1 | |
| SCHEMBL3575824 | 0.70 | ALDH1A1 (0.39) | KMT2AALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL11625714 | 0.70 | CYP1A2 (1.00) | CYP1A2CYP3A4RAB9AKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1371647-B1 | Pyridine-3-carboxylic acid derivatives and their use as intermediates | PFIZER (US) | 2005-07-13 | — | — | EP | disclosed |
| US-6916927-B2 | Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3′,5′-monophosphate phosphodiesterase (cGMP-PDE5) for the treatment of sexual dysfunction | PFIZER INC. | 2005-07-12 | — | — | US | disclosed |
| EP-0994115-B1 | Process for preparation of pyrazolo-(4,3-d)pyrimidin-7-ones and intermediates thereof | PFIZER LTD (GB) | 2005-03-02 | — | — | EP | disclosed |
| EP-1092720-B1 | Process for the preparation of pyrazolo [4,3-d] pyrimidin-7-ones-3-pyridylsulphonyl compounds and intermediates thereof | PFIZER LTD (GB) | 2005-01-12 | — | — | EP | disclosed |
| US-20040180944-A1 | Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP-PDE5) for the treatment of sexual dysfunction | PFIZER INC | 2004-09-16 | — | — | US | disclosed |
| EP-1220855-B1 | ANHYDROUS SALT | PFIZER LTD (GB) | 2004-05-19 | — | — | EP | disclosed |
| US-6723719-B1 | DYSMENORRHOEA, BENIGN PROSTATIC HYPERPLASIA (BPH), BLADDER OUTLET OBSTRUCTION, INCONTINENCE, AGINA, CONGESTIVE HEART FAILURE, ATHEROSCLEROSIS; HYPOTENSIVE AND ANTIALLERGEN AGENTS | PFIZER INC | 2004-04-20 | — | — | US | disclosed |
| EP-1371647-A2 | Pyridine-3-carboxylic acid derivatives and their use as intermediates | PFIZER INC. (US) | 2003-12-17 | — | — | EP | disclosed |
| EP-1073658-B1 | PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER (US) | 2003-08-13 | — | — | EP | disclosed |
| US-20030069422-A1 | Process for preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof | DUNN PETER JAMES (GB) | 2003-04-10 | — | — | US | disclosed |
| US-6251904-B1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | PFIZER INC. | 2001-06-26 | — | — | US | disclosed |
| WO-2001027101-A2 | ANHYDROUS SALT | PFIZER LIMITED (GB) | 2001-04-19 | — | — | WO | disclosed |
| EP-1092720-A2 | Process for the preparation of pyrazolo [4,3-d] pyrimidin-7-ones-3-pyridylsulphonyl compounds and intermediates thereof | Pfizer Limited (GB) | 2001-04-18 | — | — | EP | disclosed |
| US-6207829-B1 | CYCLIZATION OF A CORRESPONDING PYRAZOLE COMPOUND | PFIZER INC. | 2001-03-27 | — | — | US | disclosed |
| EP-1073658-A1 | PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER INC. (US) | 2001-02-07 | — | — | EP | disclosed |
| EP-0995750-A1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | PFIZER INC. (US) | 2000-04-26 | — | — | EP | disclosed |
| EP-0994115-A2 | Process for preparation of pyrazolo-(4,3-d)pyrimidin-7-ones and intermediates thereof | Pfizer Limited (GB) | 2000-04-19 | — | — | EP | disclosed |
| EP-0977756-A1 | PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION | Pfizer Limited (GB) | 2000-02-09 | — | — | EP | disclosed |
| WO-1999054333-A1 | PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER INC. (US) | 1999-10-28 | — | — | WO | disclosed |
| WO-1998049166-A1 | PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER LIMITED (GB) | 1998-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180944-A1 | Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP-PDE5) for the treatment of sexual dysfunction | PDE5A, PDE3A, PDE3B | CYP1A2 86/4885CYP3A4 191/4885RAB9A 1314/4885 |
| US-20030069422-A1 | Process for preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof | UGT2B7, CYP3A7, TOP2B | CYP1A2 43/4885CYP3A4 32/4885RAB9A 1348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.